Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
nivolumab · 1 trial · 1 indication
PFS is defined as the number of days from the date of randomization to the date of earliest disease progression (radiographic progression per RECIST version 1.1 or clinical disease progression) or death. If the participant does not experience disease progression or death, then the data will be censored at the date of the last disease assessment.
| Arm | Type | Description |
|---|---|---|
| Veliparib and nivolumab with platinum doublet chemotherapy | EXPERIMENTAL | Veliparib and nivolumab in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed) |
| Veliparib with platinum doublet chemotherapy | EXPERIMENTAL | Veliparib in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed) |
| Name | Type | Description |
|---|---|---|
| pemetrexed | DRUG | intravenous; administered on Day 1 via infusion in a 21-day cycle |
| nivolumab | DRUG | intravenous; administered on Day 1 via infusion in a 21-day cycle |
| paclitaxel | DRUG | intravenous; administered on Day 1 via infusion in a 21-day cycle |
| veliparib | DRUG | oral capsule; varying doses administered on Days -2 to 5 in a 21-day cycle |
| carboplatin | DRUG | intravenous; administered on Day 1 via infusion in a 21-day cycle |
Inclusion Criteria: * Participant must have a life expectancy greater than 12 weeks, * Participant must have cytologically or histologically confirmed Non-small Cell Lung Cancer (NSCLC). * Participant must have metastatic or advanced NSCLC (Stage IIIB or IV) that is not amenable to surgical resecti...
Top 20 of 84 competitors
Nivolumab is an investigational antibody being studied for use in Non-Small Cell Lung Cancer (NSCLC). In a completed Phase 1 trial, it was evaluated in combination with veliparib and platinum doublet chemotherapy in participants with metastatic or advanced NSCLC. The trial enrolled 25 participants in the United States.
Nivolumab is a monoclonal antibody, indicated by its -mab suffix. It is being studied in Non-Small Cell Lung Cancer, where it is combined with veliparib and platinum doublet chemotherapy. The specific molecular target is not disclosed in the available trial information.
Nivolumab is being developed by AbbVie Inc., a biopharmaceutical company traded under the ticker ABBV. The drug is currently in Phase 1 clinical development for Non-Small Cell Lung Cancer.
Nivolumab is in Phase 1 clinical development. It is an investigational drug, not yet approved, and has completed one Phase 1 trial. The completed trial studied nivolumab in combination with veliparib and platinum doublet chemotherapy for Non-Small Cell Lung Cancer.
Nivolumab has one completed clinical trial, NCT02944396, titled "Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)." This Phase 1 trial enrolled 25 participants in the United States and is now completed.
Nivolumab is not reported to have any alternative names. It is a distinct investigational monoclonal antibody being developed by AbbVie Inc. for Non-Small Cell Lung Cancer. No other names for this drug have been disclosed in the available information.